Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B-Cell Non-Hodgkin Lymphoma: early-phase trial registry
15 of 25 indexed B-Cell Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 15 currently recruiting · #652 of 28,707 conditions by registered trial count
B-Cell Non-Hodgkin Lymphoma: 25 US clinical trials tracked, 15 recruiting.
B-Cell Non-Hodgkin Lymphoma is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 4 of these trials.
Enrollment posture brief
Registry condition b-cell-non-hodgkin-lymphoma
OPEN 15 | RECR 60% | LATE 0 | EARLY 24 | RANK #652 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
B-Cell Non-Hodgkin Lymphoma lists 15 open slots (60% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for B-Cell Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
B-Cell Non-Hodgkin Lymphoma is recruiting above its size-band peers.
15 of 25 indexed trials (60%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates B-Cell Non-Hodgkin Lymphoma research.
AstraZeneca accounts for 4 of 25 trials (16%). 17 distinct sponsors appear on at least one study for this condition label.
-
Most B-Cell Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 62 among the 25 trials that report a genuine target (sentinel values excluded). 15 of those (60%) plan for fewer than 100 participants.
-
B-Cell Non-Hodgkin Lymphoma research is mostly interventional.
24 interventional and 1 observational studies make up this index (96% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
AstraZeneca
NCT04594642
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
AstraZeneca
NCT06564038
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
AstraZeneca
NCT06526793
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.
NCT04970901
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
City of Hope Medical Center
NCT06052826
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics
NCT05365659
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
NCT03017820
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
AstraZeneca
NCT07123454
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
University of Kansas Medical Center
NCT06879340
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
NCT04544592
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
NCT06242834
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
NCT06191887
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Medical University of South Carolina
NCT05702853
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT07097363
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT05432635
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Memorial Sloan Kettering Cancer Center
NCT02633111
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT03671018
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
Wake Forest University Health Sciences
NCT03505762
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
Memorial Sloan Kettering Cancer Center
NCT04148430
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03114865
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
NCT04257578
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
University of Chicago
NCT03283137
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT03677141
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
NCT04088890
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT02424968
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on B-Cell Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on B-Cell Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this B-Cell Non-Hodgkin Lymphoma page
25 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 B-Cell Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most B-Cell Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B-Cell Non-Hodgkin Lymphoma condition card totals 25 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.